We are building a pipeline of first‑in‑class, disease‑modifying small molecules derived from our function‑first genomics platform Cell-Seq. Our lead program SC6177 is a brain penetrant small molecule inhibitor of PLA2G15 – a first-in-class lysosomal target with broad potential across neurodegenerative diseases. Additional discovery programs for several neurometabolic diseases are being advanced in parallel.

Scenic Biotech’s lead program, SC6177, is a first-in-class, brain-penetrant inhibitor designed to restore lysosomal function, a fundamental biological process increasingly recognized as a key driver of neurodegenerative disease. With protein aggregation strategies (amyloid, tau) delivering limited success, the field is increasingly converging on lysosomal health as a fundamental mechanism. Positioned early in this shift, Scenic combines a novel target with brain penetrant small molecule chemistry to lead in this next wave of innovation.

SC6177 targets PLA2G15, a novel lysosomal enzyme discovered through Scenic’s proprietary Cell-Seq™ platform and published in Nature in 2025. PLA2G15 regulates Bis(monoacylglycero)phosphate (BMP), a key protecting lipid in lysosomes. Inhibiting PLA2G15 through SC6177 represents a differentiated therapeutic approach with the potential to address a broad spectrum of neurodegenerative disorders characterized by lysosomal dysfunction, including CLN3 Batten Disease, Niemann-Pick Type C, Frontotemporal Dementia and genetic forms of Parkinson’s Disease.

The program is currently advancing through IND-enabling development, with first-in-human clinical trials targeted for 2027. Our development strategy is designed to deliver initial proof-of-concept in orphan indications, followed by expansion into broader neurodegenerative populations.